Mepivacaine - Relmada Therapeutics

Drug Profile

Mepivacaine - Relmada Therapeutics

Alternative Names: MepiGel; REL-1021; TQ-1021

Latest Information Update: 17 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraQuest Biosciences
  • Developer Relmada Therapeutics
  • Class Local anaesthetics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia; Neuropathic pain
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 12 Sep 2016 Preclinical development is ongoing in USA
  • 25 Jul 2012 TheraQuest Biosciences is now called Relmada Therapeutics
  • 24 Jun 2010 Preclinical trials in Diabetic neuropathies in USA (Topical, Cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top